About 500 reports

  • RISING INCIDENCE OF LUNG CANCER
  • MARKET SIZE: GLOBAL LUNG CANCER LIQUID BIOPSY MARKET

Lung cancer liquid biopsy is one of the upcoming technologies in the in-vitro diagnostics market.

  • Laboratory
  • Lung Cancer
  • Biocept, Inc.
  • Exosome Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.

Company Overview Chapter ## Appendix: Acronyms List of Tables Summary Table : Global Market for Lung Cancer Therapeutics, by Type, Through 2023 Table ## : TNM Classification of Malignant Tumors of Lung Cancer Table ## : Five-Year Survival Rates, NSCLC and S

  • Cancer
  • Lung Cancer
  • Pathology
  • APAC
  • World
  • COSTS OF FEW LUNG CANCER DRUGS ($)
  • ELI LILLY IN GLOBAL LUNG CANCER THERAPEUTICS MARKET

Market Overview Strong prevalence of lung cancer Lung cancer is one of the most common cancer types.

  • Cancer
  • Lung Cancer
  • Therapy
  • World
  • Forecast

The 2020-2025 World Outlook for Lung Cancer Surgery ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Cancer
  • Lung Cancer
  • Pathology
  • World
  • Demand

The 2020-2025 World Outlook for Non-Small Cell Lung Cancer (NSCLC) Drugs ## INTRODUCTION ##. ## OVERVIEW ##. ## WHAT IS LATENT DEMAND AND THE P. I. E.?

  • Cancer
  • Lung Cancer
  • Pathology
  • World
  • Demand
  • RISK FACTORS AND COMORBIDITIES FOR LUNG CANCER
  • DEFINITIONS USED IN THE AJCC LUNG CANCER STAGING SYSTEM

LUNG CANCER.

  • Lung Cancer
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

Lung Cancer Therapeutics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024 ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • World
  • Market Size
  • NSCLC Therapeutics Market, Australia, Age-Specific Incidence Rate (per 100,000),
  • NSCLC Therapeutics Market, South Korea, Market Forecast, 2016-2023

Clinical Lung Cancer; ##(##): ##-## Goldstraw P, et al. (2007).

  • Lung Cancer
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novartis AG
  • Roche Group

Global Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Cancer
  • Lung Cancer
  • France
  • World
  • Forecast

Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Lung Cancer
  • France
  • Germany
  • Italy
  • World

Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027 ##.

  • Cancer
  • Lung Cancer
  • Pathology
  • World
  • Market Shares

Non-Small Cell Lung Cancer KOL Interview – NH, US Overview Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-##/ L## inhibitors to gauge his views on their current application within non-small cell lung

  • Cancer
  • Lung Cancer
  • Pathology
  • United States
  • KEY UPDATES IN ALKM+ NSCLC
  • FORECAST UPDATES WILL BE TRIGGERED BY KEY MARKET-IMPACTING EVENTS

Oncogenic and drug sensitive NTRK## rearrangements in lung cancer.

  • Lung Cancer
  • United States
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC) CONTENTS ## OVERVIEW ## ABOUT THE AUTHORS ## IMMUNO-ONCOLOGY OVERVIEW ## Immuno-oncology mechanisms and timelines ## PD-## and PD-L## inhibition ## CLINICAL TRIAL LANDSCAPE ## Active trials

  • Cancer
  • Lung Cancer
  • European Union
  • Japan
  • United States

Market Snapshot Sales of PD-##/ PD-L## targeted immunotherapies in NSCLC are forecast to grow to $##. ##bn by 2026.

  • Cancer
  • Lung Cancer
  • European Union
  • Japan
  • United States

Datamonitor Healthcare Non-Small Cell Lung Cancer KOL Interview – NY, US Overview Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-##/ L## inhibitors to gauge his views on their current application within non-sm

  • Cancer
  • Healthcare
  • Lung Cancer
  • Pathology
  • United States

Global Lung Cancer Vaccine Market & Pipeline Outlook 2022 ##.

  • Lung Cancer
  • Therapy
  • Vaccine
  • World
  • Forecast
  • 4.3.4 China Small Cell Lung Cancer (SCLC) Market by Value
  • 4.3.1 China Non-small Cell Lung Cancer (NSCLC) Market by Value

About ##% of the lung cancer are non-small cell lung carcinoma (NSCLC).

  • Lung Cancer
  • China
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

Non-small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis Table of Content Chapter ## Research Methodology ##. ## Information Procurement ##. ## Data Analysis Chapter ## Executive Summary ##. ## Market Snapshot Chapter ## Non-small Cell Lung Cancer Therapeut

  • Lung Cancer
  • Therapy
  • United States
  • Forecast
  • Market Size

SWOT Analysis in NSCLC, 2016 ## Figure ##: Novartis SWOT Analysis in NSCLC, 2016 ## Figure ##: BI SWOT Analysis in NSCLC, 2016 ## Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players Summary GlobalData has released its pharma report, “Non-Small Cell Lung

  • Cancer
  • Lung Cancer
  • World
  • Company
  • Demand
  • Lung Cancer
  • VERISANTE CORE - LUNG CANCER

With one third of lung cancers globally, China is the biggest market for our endoscopic products, and the place where we can make the biggest impact in our fight against cancer, " said Thomas Braun, CEO.

  • Lung Cancer
  • Canada
  • United States
  • Company
  • Verisante Technology, Inc.

Lung cancer is classified into three main types: non-small cell lung cancer (NSCLC), small cell lung cancer, and lung carcinoid tumor.

  • Cancer
  • Lung Cancer
  • China
  • World
  • Forecast
  • Risk Factors and Comorbidities Associated with SCLC
  • 2.3 UPCOMING REPORTS

GlobalData epidemiologists further calculated the sex-specific one- to five- year relative survival rates for SCLC lung cancer.

  • Lung Cancer
  • Japan
  • United States
  • World
  • Forecast

Europe Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Lung Cancer
  • Europe
  • France
  • Germany
  • Italy

Lung Cancer Phase ## Clinical Trials, 2016 ##.

  • Lung Cancer
  • France
  • United States
  • Market Shares
  • Market Size

Small Cell Lung Cancer Phase ## Clinical Trials, 2016 ##.

  • Lung Cancer
  • France
  • United States
  • Market Shares
  • Market Size

Europe Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Lung Cancer
  • Europe
  • France
  • Germany
  • Italy

Non-Small Cell Lung Cancer Phase ## Clinical Trials, 2016 ##.

  • Lung Cancer
  • France
  • United States
  • Market Shares
  • Market Size

Of total lung cancer incident cases, approximately ##% are the non-small cell lung cancer (NSCLC) subtype.

  • Cancer
  • Lung Cancer
  • Pathology
  • Therapy
  • Japan

Of total lung cancer incident cases, approximately ##% are the non-small cell lung cancer (NSCLC) subtype.

  • Cancer
  • Lung Cancer
  • Pathology
  • Therapy